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Abstract
Background: Oxidized low-density lipoprotein (oxLDL) uptake by macrophages plays an important role in foam
cell formation. It has been suggested the presence of heterogeneous subsets of macrophage, such as M1 and M2,
in human atherosclerotic lesions. To evaluate which types of macrophages contribute to atherogenesis, we
performed cDNA microarray analysis to determine oxLDL-induced transcriptional alterations of each subset of
macrophages.
Results: Human monocyte-derived macrophages were polarized toward the M1 or M2 subset, followed by
treatment with oxLDL. Then gene expression levels during oxLDL treatment in each subset of macrophages were
evaluated by cDNA microarray analysis and quantitative real-time RT-PCR. In terms of high-ranking upregulated
genes and functional ontologies, the alterations during oxLDL treatment in M2 macrophages were similar to those
in nonpolarized macrophages (M0). Molecular network analysis showed that most of the molecules in the oxLDL-
induced highest scoring molecular network of M1 macrophages were directly or indirectly related to transforming
growth factor (TGF)-b1. Hierarchical cluster analysis revealed commonly upregulated genes in all subset of
macrophages, some of which contained antioxidant response elements (ARE) in their promoter regions. A cluster
of genes that were specifically upregulated in M1 macrophages included those encoding molecules related to
nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-B) signaling pathway. Quantitative real-
time RT-PCR showed that the gene expression of interleukin (IL)-8 after oxLDL treatment in M2 macrophages was
markedly lower than those in M0 and M1 cells. HMOX1 gene expression levels were almost the same in all 3
subsets of macrophages even after oxLDL treatment.
Conclusions: The present study demonstrated transcriptional alterations in polarized macrophages during oxLDL
treatment. The data suggested that oxLDL uptake may affect TGF-b1- and NF-B-mediated functions of M1
macrophages, but not those of M0 or M2 macrophages. It is likely that M1 macrophages characteristically respond
to oxLDL.
Background
Atherosclerosis is a major cause of cardiovascular disease,
which is one of the leading morbidities worldwide [1].
Atherosclerosis has been suggested to be merely a lipid-
storage disease; however, it is now recognized as an
inflammatory condition of the vessel wall characterized
by infiltration of macrophages and T cells [2]. Monocytes
are recruited into the arterial intima and differentiate
into macrophages. They take up oxidized low-density
lipoprotein (oxLDL) via scavenger receptors, and then
become foam cells that play a crucial role in the initiation
of atherosclerotic lesions [3]. Foam cells have been
shown to affect many atherogenic events, including
recruitment of monocytes and neutrophils by producing
chemokines, such as monocyte chemoattractant protein
(MCP)-1 [4] and interleukin (IL)-8 [5], formation of
necrotic cores in atherosclerotic plaques [3], and produc-
tion of matrix metalloproteases (MMPs), which degrade
the extracellular matrix comprising the fibrous cap of
plaque [6]. Therefore, macrophages immunologically
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process of differentiation into foam cells in atherogenic
processes.
Over the past several decades, a number of studies
have demonstrated that macrophages do not represent a
homogenous cell population. Stein et al. described an
alternative subset of macrophages induced by IL-4, char-
acterized by high mannose receptor (MR) expression [7].
Since then, it has been demonstrated that monocyte-
derived macrophages can be polarized into two subsets
in vitro. One subset consists of classically activated
macrophages (M1 macrophages) polarized with lipopoly-
saccharide (LPS) and interferon (IFN)-g, which are char-
acterized by CD86 expression and production of
proinflammatory cytokines, such as tumor necrosis fac-
tor (TNF)-a, IL-1, and IL-6. The other subset consists
of alternatively activated macrophages (M2 macro-
phages) polarized with Th2 cytokines, such as IL-4 and/
or IL-13, which are characterized by MR expression [8].
Recently, Bouhlel et al. confirmed the presence of M2
macrophages within human atherosclerotic lesions by
identifying the expression of M2 markers, including IL-
10 and MR in human carotid plaques [9]. They also
reported that macrophages expressing M2 markers show
a different distribution from foam cells. These results
suggested the presence of heterogeneous subsets of
macrophages in human atherosclerotic lesions. However,
it remains unclear which type of macrophages differenti-
a t ei n t of o a mc e l l so rh o wt h e yc o n t r i b u t et o
atherogenesis.
The present study was performed to elucidate the
contributions of M1 and M2 macrophages to atherogen-
esis during differentiation into foam cells. Martinez et
al. investigated the polarization of human monocytes
toward M1 or M2 macrophages using cDNA microarray
analysis, and found distinct sets of genes specifically
upregulated in either subset of macrophages [10]. Cho
et al. also examined the transcriptional differences in
human monocyte-derived macrophages during oxLDL
uptake by cDNA microarray analysis [11]. However,
there have been no previous studies of the whole tran-
scriptional alterations in human M1 or M2 macrophages
during oxLDL uptake. To investigate the roles of these
macrophage subsets during differentiation into foam
cells, we examined the transcriptional alterations of M1
or M2 macrophages during oxLDL treatment.
Methods
Materials
Lymphoprep was purchased from AXIS-SHILD (Rode-
lokka, Oslo, Norway). Dulbecco’s Modified Eagle’sM e d -
ium: Nutrient Mixture F-12 (DMEM/F12) was obtained
from Invitrogen (Carlsbad, CA), and RPMI-1640 culture
medium (endotoxin-free) was from Sigma-Aldrich (St.
Louis, MO). Recombinant human macrophage-colony
stimulating factor (M-CSF), IFN-g,a n dI L - 4w e r e
obtained from R&D Systems (Minneapolis, MN). LPS
from Escherichia coli (serotype O111:B4) was obtained
from List Biological Laboratories Inc. (Campbell, CA).
OxLDL (endotoxin level < 0.5 EU/ml), which was pre-
pared with 3.5 μMC u S O 4 in PBS at 37°C for 24 h, was
purchased from Biomedical Technologies (Stoughton,
MA). The average level of thiobarbituric acid-reactive
substances (TBARS) in this study was 76.23 ± 7.89 nmol
malondialdehyde equivalents/mg LDL protein (mean ±
SD). Anti-CD14 antibody, anti-CD86 antibody, and anti-
MR antibody were obtained from eBioscience (San
Diego, CA). All procedures were performed under endo-
toxin-free conditions.
Cells
Peripheral blood mononuclear cells (PBMCs) were
obtained from healthy volunteers with informed consent
from buffy coats by density-gradient centrifugation
using Lymphoprep. The purity of monocytes was > 95%
as determined by flow cytometric analysis using anti-
CD14 antibody (data not shown). The monocytes were
suspended in DMEM/F12, and plated onto tissue culture
dishes at a density of 1 × 10
6 cells/cm
2 for 2 h at 37°C.
The adherent cells were differentiated into macrophages
by incubation with 100 ng/mL M-CSF in RPMI-1640
medium supplemented with 20% fetal calf serum (FCS)
for 7 days (these cells were defined as M0 macro-
phages). Macrophage polarization was performed as
described by Martinez et al. with slight modifications
[10]. To obtain M1 or M2 macrophages, M0 macro-
phages were further incubated with 10 pg/mL LPS plus
20 ng/mL IFN-g or 20 ng/mL IL-4 in RPMI-1640 with
5% FCS for 18 h, respectively. After polarization, media
were removed, and each subset of macrophages was
incubated for a further 6 h in the presence or absence
of 100 μg/mL oxLDL. The study was approved by the
Ethical Committee of Juntendo University.
Flow cytometric analysis
The M1 or M2 polarized macrophages were washed
with PBS. After washing, cells were stained with PE-
Cy5- or FITC-conjugated antibodies or with correspond-
ing isotype controls for 20 min at 4°C. Then, flow cyto-
metry was performed to determine the expression of
cell surface antigens using FACSCalibur (BD Bios-
ciences, Franklin Lakes, NJ), as described previously
[12]. Data were analyzed using Cell Quest software (BD
Biosciences).
Quantitative real-time RT-PCR
Total RNA was extracted and purified from macrophages
using an RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA
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ExScript RT-PCR Kit (Takara-Bio, Shiga, Japan). Primers
were selected using Perfect Real-Time Primer Support
System provided by Takara. Real-time RT-PCR was per-
formed using SYBR Premix Ex Taq (Takara-Bio) and an
ABI 7900HT Sequence Detector System (Applied Biosys-
tems, Foster City, CA). The amplification program
included an initial denaturation step at 95°C for 10 s, 40
cycles of denaturation at 95°C for 10 s, and annealing
and extension at 60°C for 30 s. After amplification, disso-
ciation curves were acquired to determine the specificity
of PCR products. The relative cDNA concentrations were
established using a standard curve plotted with sequential
tenfold dilutions of cDNA synthesized from QPCR
Human Reference Total RNA (Stratagene, La Jolla, CA).
The data were normalized relative to peptidylprolyl iso-
merase A (PPIA) as an internal control.
cDNA microarray analysis
cDNA synthesis and aminoallyl labeling of RNA were
performed using an amino-allyl RNA amplification kit
(Sigma-Aldrich) according to the manufacturer’s
instructions. The Cy3- or Cy5-labeled aminoallyl RNA
was concentrated using Microcon YM-30 (Millipore,
Bedford, MA), mixed with hybridization buffer supplied
with the kit, and denatured at 95°C for 2 min. The
hybridization mixture was applied onto a “3D-Gene”
human oligo chip 25 k (Toray Industries, Tokyo, Japan),
and incubated according to the manufacturer’si n s t r u c -
tions. After washing and drying the DNA chip slides,
the fluorescent signals were quantified by ScanArray
Lite (PerkinElmer Life Sciences, Boston, MA) and ana-
lyzed using ScanArray Express software. After subtrac-
tion of the mean background level, the fluorescence
intensity was normalized relative to the mean sample
intensity in each chip. Any given gene was analyzed if
its normalized intensity was more than 2
-4. We defined
genes showing a change in expression of > 2-fold during
oxLDL treatment as significantly up- or downregulated
(log2 ratios were greater than +1 or less than -1).
Ingenuity pathway analysis
Ingenuity Pathway Analysis (IPA) software (version 8.7;
Ingenuity Systems, Redwood, CA) was utilized to deter-
mine the possible biological pathways and intermolecu-
lar networks between candidate genes. A detailed
description of IPA software can be found on the Inge-
nuity Systems website http://www.ingenuity.com/. The
significantly up- or downregulated genes were overlaid
onto a global molecular network developed from infor-
mation contained in the Ingenuity Knowledge Base.
Functional gene ontology analysis identified the biologi-
cal functions that were most significant to molecules in
the network. The network molecules associated with
biological functions in the Knowledge Base were consid-
ered for the analysis. Right-tailed Fisher’se x a c tt e s tw a s
used to calculate the P-values determining the probability
that each biological function assigned to that network was
due to chance alone. IPA generates significant biological
networks that are particularly enriched with the genes of
interest, called “focus genes.” It calculates a network score
that takes into account the number of focus genes and the
size of the networks, indicating the likelihood of focus
genes in a network being found together by chance. The
higher the score, the lower is the probability of finding the
observed Network Eligible Molecules in a given network
by chance. Network analysis produces a graphical repre-
sentation of the molecular relationships between the iden-
tified genes. Molecules are represented as nodes, and the
biological relationship between two nodes is represented
as a line. All relationships are supported by at least 1 refer-
ence from the literature, from a textbook, or from canoni-
cal information stored in the Knowledge Base.
Statistical analysis
The data were expressed as the means ± SD and were
analyzed for significant differences by one-way or two-
way analysis of variance (ANOVA) and, Bonferroni’s
post hoc test using GraphPad Prism (version 5.00;
GraphPad Software, La Jolla, CA).
Results
Characteristics of M1 or M2 polarized macrophages
Human monocyte-derived macrophages cultured for 7
days in the presence of M-CSF can be polarized toward
M1 macrophages by further treatment with 100 ng/mL
LPS plus 20 ng/mL IFN-g for 18 h [10]. However, under
our experimental conditions, almost all cells were
damaged by such high a concentration of LPS, as demon-
strated by trypan blue staining (data not shown). There-
fore, we differentiated M-CSF-treated monocytes into
M1 macrophages by incubation with 10 pg/mL LPS plus
20 ng/mL IFN-g. We confirmed the polarized cells as M1
and M2 macrophages by quantitative real-time RT-PCR
and flow cytometric analysis (Figure 1). Consistent with
the previous report of Martinez et al. [10], M1 macro-
phages showed higher levels of proinflammatory cytokine
mRNA expression, such as TNF-a,I L - 1 b, and IL-6, than
M0 or M2 macrophages. In contrast, M2 macrophages
showed markedly elevated expression of MRC1, which
encodes MR (Figure 1A). The level of CD86 expression
on M1 macrophages was higher than that on M2 macro-
phages, while MR was expressed on M2 macrophages
but not on M1 macrophages (Figure 1B).
Transcriptional profile
After confirming that the 2 subsets of macrophages
were properly polarized to M1 or M2 macrophages,
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Page 3 of 18Figure 1 Expression of M1 and M2 macrophage polarized markers in human monocyte-derived macrophages.A .TNFa, IL1b,a n dIL6
gene expression as markers of M1, and MRC1 gene expression as a marker of M2 were analyzed by RT-PCR. Each panel shows data from one of
3 representative experiments. B. Surface expression of CD86 (M1 marker) and mannose receptor (MR) (M2 marker) were analyzed by flow
cytometry. The level of CD86 expression was higher in M1 than in M2 macrophages, while the expression level of MR was higher in M2 than in
M1 macrophages.
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the alterations during oxLDL treatment. Of the 25392
probe sets on “3D-Gene” human oligo chip 25 k, we
eliminated 1125 probe sets as controls and backgrounds.
Any given gene was eliminated if its normalized intensity
w a sl e s st h a n2
-4.W ea l s oe l i m i n a t e dn o n - a l t e r e dg e n e s
that showed changes in expression level of less than 2-
fold during oxLDL treatment. Finally, we identified 2025,
2265, and 2249 genes that were significantly up- or
downregulated in M0, M1, and M2 macrophages, respec-
tively (Figure 2). Among these genes, 1526, 1819, and
1880 genes were upregulated in M0, M1, and M2 macro-
phages by oxLDL treatment, respectively (All transcrip-
tional profiles are shown in Additional file 1). Table 1
shows the top 30 genes that were most markedly upregu-
lated by oxLDL. IL8, TRIM16,a n dADM were commonly
upregulated in all subsets of macrophages. Twenty-eight
genes in the top 30 upregulated genes in M2 macro-
phages (93% of the top 30 genes) were also upregulated
in M0, while 15 genes in the top 30 upregulated genes in
M2 macrophages were upregulated in M1 cells.
Functional gene ontology
To identify oxLDL treatment-related biological functions
of polarized macrophages, bioinformatics aspects of dif-
ferentially expressed genes during oxLDL treatment
were further analyzed using IPA software. The 1566,
1738, and 1749 genes of M0, M1, and M2 macrophages
were identified by IPA software as functionally inten-
tional genes, and categorized into 65, 84, and 80 groups
according to functional gene ontology, respectively. Fig-
ure 3 shows the top 10 functional ontology categories
which contain the molecules altered by oxLDL treat-
ment. Eight of the top 10 ontology categories of M0
macrophages were also found in the top 10 of M2
macrophages, whereas only 3 ontology categories of M1
macrophages were found in the top 10 of M2.
Molecular network analysis
We performed molecular network analysis using IPA soft-
ware to elucidate the molecular relationships when each
subset of macrophages was treated with oxLDL. The top 5
highly scoring networks of each subset are shown in Table
2. Among these networks, the highest scoring network
was found in M1 macrophages as Network #1, including
molecules related to “carbohydrate metabolism,”“ DNA
replication, recombination and repair,” and “embryonic
development.” Interestingly, most of the molecules in net-
work #1 were related to transforming growth factor
(TGF)-b1 directly or indirectly (Figure 4).
Hierarchical cluster analysis
Hierarchical cluster analysisa l l o w su st ov i s u a l l yc o m -
prehend differential patterns over multiple microarray
datasets. To analyze the hierarchical clusters over sub-
sets of macrophages, we constructed a heat map where
red and green indicated up- and downregulation, respec-
tively (Figure 5). We employed 3196 genes, expression
levels of which were significantly altered by oxLDL
treatment in at least one subset of macrophages. A total
of 251 genes were commonly identified as upregulated
genes in all subsets of macrophages, including TRIM16,
HMOX1, TXNRD1, GCLM,a n dDUSP1, all of which
contain an antioxidant response element (ARE) in their
promoter regions, which serves as a binding site for
nuclear factor erythroid 2-related factor 2 (Nrf2). Hier-
archical cluster analysis identified 3 clusters the genes of
which were upregulated in one subset but not in the
other subsets (Figure 5). Cluster A included 17 anno-
tated genes that were upregulated in M0, but not in the
other subsets (Table 3). The genes in cluster A belonged
to ontology categories including “cell-mediated immune
response,”“ cellular movement,”“ hematological system
development and function,” and “immune cell traffick-
ing.” There were 72 annotated genes in cluster B, which
were specifically upregulated in M1. These 72 genes
were related to “gene expression” and “cellular develop-
ment.” They included NFKB2, encoding nuclear factor
of kappa light polypeptide gene enhancer in B-cells (NF-
B), and PIK3R4, encoding phosphoinositide-3-kinase
(PI3K), both of which are molecules related to the NF-
B signaling pathway. In cluster C, 28 annotated genes
were identified as specifically upregulated in M2. These
genes were associated with “carbohydrate metabolism,”
“lipid metabolism,” and “small molecule biochemistry.”
Quantitative real-time RT-PCR analysis
All data from cDNA microarray analysis in the present
study were comparisons between cells with and without
oxLDL treatment. To compare gene expression levels
among subsets of macrophages, we performed quantita-
tive real-time RT-PCR for two genes: IL8 listed in the
top 30 genes that were commonly upregulated in all
subsets of macrophages (Table 1) and HMOX1 encoding
heme oxygenase (HO)-1 as a representative of genes
containing an ARE.
Consistent with previous reports, the expression levels
of IL8 were higher in non-stimulated M1 macrophages
than in M2 [10], and oxLDL treatment induced higher
levels of IL8 expression in M0 macrophages [13,14] (Fig-
ure 6A). Moreover, the expression level of IL8 was sig-
nificantly upregulated by oxLDL treatment in M1
macrophages, whereas its expression level after oxLDL
treatment in M2 was markedly lower than those in M0
and M1 macrophages (P < 0.05). It has been known for
several decades that oxLDL treatment increases, while
IL-4 treatment decreases IL-8 production in human
monocyte-derived macrophages [13,15]. However, a
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Page 5 of 18Figure 2 Genes showing significantly altered expression in oxLDL-treated macrophages on cDNA microarray analysis.T h e
logarithmically transformed intensities of all the genes in oxLDL-treated macrophages were plotted against those in non-treated macrophages
(Left panels). Genes were eliminated if the normalized intensity was less than 2
-4, or if the change in alteration during oxLDL treatment was less
than 2-fold (Right panels). Finally, 2025, 2265, and 2249 genes were identified as showing significantly regulated expression in M0, M1, and M2
macrophages, respectively.
Hirose et al. Lipids in Health and Disease 2011, 10:1
http://www.lipidworld.com/content/10/1/1
Page 6 of 18Table 1 Genes upregulated by oxLDL in polarized macrophages
The top 30 genes upregulated by oxLDL in M0
Gene Symbol Ref Seq ID M0 M1 M2 NCBI official full name
IL8 NM_000584 6.200 3.200 5.177 interleukin 8
CCL1 NM_002981 6.028 0.937 - chemokine (C-C motif) ligand 1
SERPINB2 NM_002575 5.485 - - serpin peptidase inhibitor, clade B (ovalbumin), member 2
IL1B NM_000576 5.162 2.700 2.684 interleukin 1, beta
PTGS2 NM_000963 4.985 - - prostaglandin-endoperoxide synthase 2
TM4SF1 NM_014220 4.836 - 1.238 transmembrane 4 L six family member 1
CCL19 NM_006274 4.834 0.368 - chemokine (C-C motif) ligand 19
POPDC3 NM_022361 4.557 1.491 - popeye domain containing 3
INHBA NM_002192 4.476 2.335 - inhibin, beta A
CKB NM_001823 4.378 0.920 2.107 creatine kinase, brain
IFIT1 NM_001001887 4.152 0.717 5.734 interferon-induced protein with tetratricopeptide repeats 1
CCL5 NM_002985 4.075 -0.218 1.616 chemokine (C-C motif) ligand 5
IFIT5 NM_012420 4.039 - - interferon-induced protein with tetratricopeptide repeats 5
TNFAIP6 NM_007115 4.033 0.019 - tumor necrosis factor, alpha-induced protein 6
TRIM16 NM_006470 3.990 2.992 3.453 tripartite motif-containing 16
ADM NM_001124 3.973 4.807 3.202 adrenomedullin
CCL4L2 NM_207007 3.905 1.321 0.448 chemokine (C-C motif) ligand 4-like 2
ISG20 NM_002201 3.839 0.952 4.442 interferon stimulated exonuclease gene 20kDa
EREG NM_001432 3.726 2.793 - epiregulin
CSF2 NM_000758 3.644 1.605 0.724 colony stimulating factor 2 (granulocyte-macrophage)
RHOF NM_019034 3.638 - 3.020 ras homolog gene family, member F (in filopodia)
GSTM3 NM_000849 3.632 2.635 2.543 glutathione S-transferase mu 3 (brain)
AKR1C3 NM_003739 3.497 2.490 3.432 aldo-keto reductase family 1, member C3
CYP7B1 NM_004820 3.482 - - cytochrome P450, family 7, subfamily B, polypeptide 1
CCL4 NM_002984 3.466 0.742 -0.123 chemokine (C-C motif) ligand 4
CCL24 NM_002991 3.433 0.413 - chemokine (C-C motif) ligand 24
NT5E NM_002526 3.406 -- 5 ’-nucleotidase, ecto (CD73)
IFI44L NM_006820 3.325 -0.074 4.474 interferon-induced protein 44-like
COX11 NM_004375 3.306 1.946 1.111 COX11 cytochrome c oxidase assembly homolog (yeast)
NOL12 NM_024313 3.281 0.937 1.313 nucleolar protein 12
The top 30 genes upregulated by oxLDL in M1
Gene Symbol Ref Seq ID M0 M1 M2 NCBI official full name
ADM NM_001124 3.973 4.807 3.202 adrenomedullin
S1RT5 NM_012241 3.039 3.486 2.137 sirtuin 5
CXCR5 NM_032966 1.986 3.437 1.815 chemokine (C-X-C motif) receptor 5
KLHL21 NM_014851 2.380 3.324 - kelch-like 21 (Drosophila)
IL8 NM_000584 6.200 3.200 5.177 interleukin 8
DPYSL3 NM_001387 3.064 3.192 3.497 dihydropyrimidinase-like 3
RAB43 NM_198490 1.264 3.003 3.324 RAB43, member RAS oncogene familyprovided
TRIM16 NM_006470 3.990 2.992 3.453 tripartite motif-containing 16
C1orf66 NM_015997 0.382 2.970 1.953 chromosome 1 open reading frame 66
PIP4K2A NM_005028 2.325 2.967 3.127 phosphatidylinositol-5-phosphate 4-kinase, type II, alpha
AGAP3 NM_031946 1.289 2.945 1.091 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3
INPP4A NM_001566 0.129 2.872 1.872 inositol polyphosphate-4-phosphatase, type I, 107kDa
DAGLA NM_006133 1.545 2.834 2.807 diacylglycerol lipase, alpha
EREG NM_001432 3.726 2.793 - epiregulin
AGAP11 NM_133447 0.971 2.791 2.318 ankyrin repeat and GTPase domain Arf GTPase activating protein 11
ADAMTS10 NM_030957 0.683 2.773 0.952 ADAM metallopeptidase with thrombospondin type 1 motif, 10
KCP NM_199349 1.269 2.746 1.861 kielin/chordin-like protein
ZFAT NM_020863 1.758 2.743 2.002 zinc finger and AT hook domain containing
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LZTR1 NM_006767 1.092 2.714 3.134 leucine-zipper-like transcription regulator 1
MON1B NM_014940 0.234 2.712 -0.754 MON1 homolog B (yeast)
IL1B NM_000576 5.162 2.700 2.684 interleukin 1, beta
STAM NM_003473 -0.222 2.697 -0.150 signal transducing adaptor molecule (SH3 domain and ITAM motif) 1
MAFG NM_032711 2.775 2.684 2.997 v-maf musculoaponeurotic fibrosarcoma oncogene homologG (avian)
OSGIN1 NM_182981 2.427 2.672 2.002 oxidative stress induced growth inhibitor 1
ZNF673 NM_017776 0.606 2.669 - zinc finger family member 673
IREB2 NM_004136 - 2.648 - iron-responsive element binding protein 2
GSTM3 NM_000849 3.632 2.635 2.543 glutathione S-transferase mu 3 (brain)
UBR2 NM_015255 2.160 2.619 2.371 ubiquitin protein ligase E3 component n-recognin 2
SFT2D3 NM_032740 1.146 2.577 1.609 SFT2 domain containing 3
FAM70A NM_017938 - 2.577 2.614 family with sequence similarity 70, member A
The top 30 genes upregulated by oxLDL in M2
Gene Symbol Ref Seq ID M0 M1 M2 NCBI official full name
IFIT2 NM_001547 2.559 - 5.893 interferon-induced protein with tetratricopeptide repeats 2
IFIT1 NM_001001887 4.152 0.717 5.734 interferon-induced protein with tetratricopeptide repeats 1
IL8 NM_000584 6.200 3.200 5.177 interleukin 8
MX2 NM_002463 2.482 0.562 4.552 myxovirus (influenza virus) resistance 2 (mouse)
IFI44L NM_006820 3.325 -0.074 4.474 interferon-induced protein 44-like
ISG20 NM_002201 3.839 0.952 4.442 interferon stimulated exonuclease gene 20kDa
IDO1 NM_002164 - 0.623 4.335 indoleamine 2,3-dioxygenase 1
PLSCR1 NM_021105 2.002 -0.179 4.119 phospholipid scramblase 1
IFIT3 NM_001549 2.306 -0.483 3.943 interferon-induced protein with tetratricopeptide repeats 3
SGPP2 NM_152386 3.229 - 3.626 sphingosine-1-phosphate phosphatase 2
OR9I1 NM_001005211 2.923 1.683 3.574 olfactory receptor, family 9, subfamily I, member 1
VNN1 NM_004666 0.568 0.896 3.569 vanin 1
DPYSL3 NM_001387 3.064 3.192 3.497 dihydropyrimidinase-like 3
TRIM16 NM_006470 3.990 2.992 3.453 tripartite motif-containing 16
EPSTI1 NM_033255 2.678 -0.642 3.439 epithelial stromal interaction 1 (breast)
AKR1C3 NM_003739 3.497 2.490 3.432 aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
RAB43 NM_198490 1.264 3.003 3.324 RAB43, member RAS oncogene family
APOL6 NM_030641 1.925 0.723 3.291 apolipoprotein L, 6
USP18 NM_017414 1.686 0.052 3.288 ubiquitin specific peptidase 18
ADM NM_001124 3.973 4.807 3.202 adrenomedullin
RSAD2 NM_080657 1.858 0.083 3.194 radical S-adenosyl methionine domain containing 2
LZTR1 NM_006767 1.092 2.714 3.134 leucine-zipper-like transcription regulator 1
PIP4K2A NM_005028 2.325 2.967 3.127 phosphatidylinositol-5-phosphate 4-kinase, type II, alpha
CSF2RA NM_172247 1.683 2.109 3.115 colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)
TNFRSF9 NM_001561 2.899 1.702 3.100 tumor necrosis factor receptor superfamily, member 9
ARHGAP44 NM_014859 1.136 1.919 3.053 Rho GTPase activating protein 44
RHOF NM_019034 3.638 - 3.020 ras homolog gene family, member F (in filopodia)
CWF19L1 NM_018294 1.271 2.098 3.005 CWF19-like 1, cell cycle control (S. pombe)
MAFG NM_032711 2.775 2.684 2.997 v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian)
TNFRSF4 NM_003327 1.815 1.376 2.974 tumor necrosis factor receptor superfamily, member 4
Non-polarized (M0) and polarized M1 and M2 macrophages were treated with or without oxLDL for 6 h. The changes in gene expression were analyzed by cDNA
microarray analysis as described in the Materials and methods section. The top 30 upregulated genes in each subset of macrophages are listed. The values
denote fold changes (log2 ratio) of normalized intensities during oxLDL treatment. Letters in boldface indicate genes that were also upregulated by more than 2-
fold in the two other subsets. “-” indicates genes that did not show significantly altered expression. Twenty-eight of the top 30 upregulated genes in M2
macrophages (93% of the top 30 genes) were also upregulated in M0, while 15 genes in the top 30 upregulated genes in M2 macrophages were upregulated in
M1 cells.
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Page 8 of 18Figure 3 Gene ontology analysis. The genes showing significantly upregulated expression in oxLDL-treated macrophages were functionally
categorized into groups according to gene ontology. The top 10 functional ontology categories in each subset of macrophages (M0, M1, and
M2) are shown in order of P-value. Right-tailed Fisher’s exact test was used to calculate the P-value determining the probability that each
biological function assigned to that network was due to chance alone. Eight of the top 10 ontology categories were found in both M0 and M2.
*Common in M0 and M1. **Common in M0 and M2. *** Common in M0, M1, and M2.
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Page 9 of 18Table 2 Molecular network analysis using IPA
Top 5 Networks in M0
ID Molecules in Network Score Focus
Molecules
Top Functions
#1 BARX2, CD226, CRABP1, CTH, Cytokeratin, FOLR2, FOS, GCLM, GCNT1, HHEX, HTATIP2,
IGDCC3, KCNJ2, KRT8, KRT18, KRT20, KRT6A, LPCAT3, MAF, MAFB, MAFF, MAFG, MT1A,
musculoaponeurotic fibrosarcoma oncogene, NFE2L3, NRF1, PAX6, PLAGL1, PVR, S100P,
TGFBI, TH1 Cytokine, TLE1, TMSB4, TMSB4X
33 31 Cellular Assembly and
Organization,
Cellular Function and Maintenance,
Hair and Skin Development and
Function
#2 Alpha tubulin, APEX2, ARRDC3, CALB2, Calbindin, CSF1, CXORF21, DHCR24, DUB, EHMT2,
FAM105A, FAM107A, GSC, HDAC6, HOOK2, LMO2, LRRC58, MIR124, NTRK3, oxidoreductase,
POU5F1, PPP1R12C, REST, RYK, STAU1, TRPM2, TSPAN14, Tubulin, USP12, USP28, USP34,
USP41, USP48, USP49, ZBED3
28 29 Auditory and Vestibular System
Development and Function,
Genetic Disorder,
Metabolic Disease
#3 ANAPC1, ANAPC2, ANAPC5, APC, ASNS, BIRC3, CD3EAP, CDC20, CHD2, CKAP2, Cpt, CPT2,
Cyclin A, DTYMK, E3 RING, EIF5, GLCE, GPC1, HEXIM1, HGF, IMPDH2, Integrin alpha V beta
3, ISG20, JMJD1C, MYL12A, NAMPT, POLR1A, SLC40A1, SPATC1, SPDEF, TMEM158, TOPBP1,
UBR2, Vegf, VHL
28 29 Protein Degradation, Protein
Synthesis,
Cardiovascular System
Development and Function
#4 ALDH2, ASXL1, C14ORF1, CBX4, CCDC106, CDK5RAP2, Cyclooxygenase, DIO3, DUSP8, FHL1,
JDP2, LSM2, MIP1, MYBPC3, P38 MAPK, PCGF2, PHYHIP, PLEKHN1, PORCN, SEMA7A, SENP2,
Stat1 dimer, STK36, SUFU, Tnf receptor, TNFRSF9, TNFRSF11A, TNFSF9, TRAF, TRAF1, TRAF5,
TRAF2-TRAF5, TRAIP, TREM1, WNT4
27 28 Cellular Assembly and
Organization,
Cellular Function and Maintenance,
Skeletal and Muscular System
Development and Function
#5 ANKRD29, APEX1, BAG5, CKB, CKMT1B, CNOT3, CNOT6, CNOT8, Creatine Kinase, DNAJA4,
DNAJB6, DNAJC15, DNMBP, Fibrinogen, Hsp70, Hsp90, Hsp22/Hsp40/Hsp90, HSPA2,
HSPA1A, ICAM1, IFT52, IP6K2, MIR1, Nos, Pka catalytic subunit, PLSCR1, SH3KBP1, SLC25A30,
SPRY2, SRXN1, TIMP3, TNKS1BP1, TNPO2, TRIM2, XPNPEP3
26 27 Cellular Assembly and
Organization,
Cellular Development,
Cellular Growth and Proliferation
Top 5 Networks in M1
ID Molecules in Network Score Focus
Molecules
Top Functions
#1 ABCD1, AQP8, C13ORF15, CALML4, CCNE2, CDC7, DBF4, FXYD6, GALM, GIN1, GYG1,
GYG2, GYS1, H1FX, HNMT, HYAL2, LPCAT3, ORC2L, ORC5L, ORC6L, OVOL1, PDLIM5,
PHGDH, PSPH, RBM19, RBMS3, SBNO2, SEMA7A, SLC23A2, SLC25A14, SLC35A1,
TBC1D1, TGFB1, TRIM7, UGDH
41 35 Carbohydrate Metabolism,
DNA Replication,
Recombination, and Repair,
Embryonic Development
#2 ATAD3B, CAPZB, CHTF18, CPD, CPT2, FXC1, FXYD1, GAMT, GPC1, GTF3C2, GTF3C4, HMG
CoA synthase, HMGCS1, HNRNPA0, IQGAP3, IREB2, LMNB2, LSM2, LSM6, LSM7, MINA,
Mir125b (mouse), MYC, Ndpk, NME2, NME6, NME7, PDS5B, RAD21, RANBP6, REC8, RFX2,
RNGTT, RRM2B, TOR2A
34 32 Cellular Assembly and
Organization,
Genetic Disorder,
Metabolic Disease
#3 ACTN4, APEX2, ATRX, DNA-directed DNA polymerase, Erm, HOOK2, ICAM1, IGSF8, LAS1L,
LIG3, LIG4, LRSAM1, MARCH3, MYOZ1, NEIL1, NOM1, PNKP, POLE2, POLG2, POLM, RNF2,
RNF6, RNF10, RNF25, RNF166, RNF185, SLC9A1, TRIM37, TRP, TRPC4, UBE2D2, UBE2E3, UBE2
H (includes EG:7328), VIL1, ZNRF1
34 32 DNA Replication, Recombination,
and Repair,
Gene Expression,
Cell-mediated Immune Response
#4 ARL15, BRD1, BTBD2, C14ORF1, C1ORF103, CCDC106, CCDC90B, CD3EAP, CDKN3, DNA-
directed RNA polymerase, EGLN1, EHMT2, FEZ1, FXR1, GTF3A, histone-lysine N-
methyltransferase, KBTBD7, KIF11, KIF2C, KLK10, LMO2, MELK, POLR1A, POLR3 D, POLR3E,
POLR3F, RIT1, SETDB1, STAB2, THAP8 (includes EG:199745), TLE1, TMSB4X, UNC119, Vegf,
ZNF24 (includes EG:7572)
30 32 Cell Cycle,
Cellular Assembly and
Organization,
DNA Replication, Recombination,
and Repair
#5 ABCC1, ABCD3, ACIN1, ATP5B, ATPase, CRISPLD2 (includes EG:83716), DTX1, DUSP1, E2F1,
FABP1, FAM177A1, GRAP, IL34, Immunoglobulin, INHBA, INHBC, LIF, MAFF, MARK4, MIR124,
MYH9, NAA15, NOTCH1, POMC, RDH10, RSF1, RYK, SKIV2L, SLC22A18AS, STAB1, SYNGR2,
Trypsin, WRN (includes EG:7486), WWP1, ZNF790
30 31 Cellular Development,
Nervous System Development and
Function,
Hematological System
Development and Function
Top 5 Networks in M2
ID Molecules in Network Score Focus
Molecules
Top Functions
#1 AKR1C3, ARL15, C1ORF103, CETN3, DCP1A, DCTPP1, DDX6, DDX20, DNA-directed RNA
polymerase, DUB, ETV3, FILIP1L, FXYD6, GANAB, GSTM3 (includes EG:2947), GTF3C4, GXYLT1,
JMJD1C, NUP155, POLR1A, POLR1E, POLR3F, PRMT1, RHOF, RIF1, SDCCAG8, SNRPA1, TARS,
TRAF6, UNC119, USP20, USP41, USP45, VHL, ZFP161
36 33 Infection Mechanism,
Infectious Disease,
Cell Cycle
#2 ATN1, BANP, C8ORF4, CBFA2T2, CLK2, CLOCK, CRY1, DBP, EIF2B1, Fascin, H1FX, HIST1H2AE
(includes EG:3012), Histone H1, HNRNPL, Importin beta, KHDRBS3, KIAA0913, LBR, LTBP4,
LTC4 S, MAST2, OGG1, Pkc(s), RNF19A, SAFB, SDCBP2, SLC20A2, SRPK1, STK36, SUFU,
TIMELESS, TM4SF1, TPM2, XPC, ZNF652
32 31 Behavior,
Nervous System Development and
Function,
Lipid Metabolism
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Page 10 of 18recent report of microarray analysis indicated that
oxLDL treatment induced no changes in human mono-
cyte-derived macrophages [11]. This may have been due
to various factors, such as individual variations or dura-
tion of oxLDL treatment [16].
HO-1 is expressed in vascular endothelial cells and
macrophages in the early stages of atherosclerotic
lesions and in foam cells in the advanced stages, and is
known for its antiinflammatory actions [17,18]. HMOX1
is known to be upregulated by oxidized phospholipids in
murine macrophages polarized toward M1 or M2 [19].
Treatment with oxLDL yielded markedly higher levels of
HMOX1 expression in all subsets of macrophages: i.e.,
7.6-fold (P < 0.0005), 5.8-fold (P < 0.05), and 5.9-fold (P
< 0.05) changes in M0, M1, and M2 macrophages com-
pared to corresponding non-treated controls, respec-
tively. HMOX1 gene expression levels were almost the
same in all 3 subsets of macrophages even after oxLDL
treatment (Figure 6B).
Discussion
In the present study, we demonstrated transcriptional
alterations during oxLDL treatment, which has been
suggested to be a model of the early stages of foam cell
formation, in human polarized macrophages. Our study
demonstrated that: 1) 93% of the top 30 genes upregu-
lated by oxLDL treatment in M2 macrophages were also
upregulated in M0; 2) the top 10 functional ontology
categories in M2 macrophages were similar to those in
M0; 3) almost all of the molecules in the highest scoring
molecular network of M1 were related either directly or
indirectly to TGF-b1; 4) there were commonly upregu-
lated genes in all subset of macrophages, some of which
contained ARE in their promoter regions; 5) hierarchical
cluster analysis revealed a cluster specifically upregu-
lated in M1, including genes encoding molecules related
to the NF-B signaling pathway; 6) in quantitative real-
time RT-PCR, the level of IL8 gene expression after
oxLDL treatment in M2 macrophages was markedly
lower than those in M0 and M1 macrophages; and 7)
HMOX1 gene expression levels were almost the same in
all 3 subsets of macrophages even after oxLDL
treatment.
The top genes expression of which was upregulated by
oxLDL treatment in M2 but not M1 macrophages were
highly correlated with the genes that were upregulated
in M0 (Table 1). Moreover, the top altered ontology
categories during oxLDL treatment in M2 macrophages
were more similar to those of M0 than M1 (Figure 3). It
has been reported that M-CSF-induced macrophages
(M0 macrophages in the present study) have a similar
transcriptional profile to M2 macrophages [10]. The
transcriptional alteration during oxLDL treatment in M2
macrophages was also relatively similar to that in M0
macrophages but not M1 cells (Table 1 and Figure 3).
The data of hierarchical cluster analysis are shown in Fig-
u r e5 .C o m m o n l yu p r e g u l a t ed genes in all subsets of
macrophages included some ARE-containing genes; e.g.,
TRIM16, HMOX1, TXNRD1, GCLM,a n dDUSP1.
TRIM16, HMOX1, TXNRD1, GCLM, and DUSP1 encode
tripartite motif-containing 16 (TRIM16), HO-1, thiore-
doxin reductase (Txnrd) 1, glutamate-cysteine ligase, modi-
fier subunit (GCLM), and dual specificity phosphatase
(DUSP) 1, respectively. These genes were upregulated dur-
ing oxLDL treatment in all subsets of macrophages in the
present study. ARE is a binding site for the transcription
factor Nrf2 [20]. The Nrf2-ARE pathway plays a crucial
role in protection against oxidative stress [21]. On expo-
sure to oxidative stress, Nrf2 translocates to the nucleus,
binds to the ARE [22], and activates the genes, including
TRIM16, HMOX1, TXNRD1, GCLM,a n dDUSP1.T h e s e
data were consistent with the recent report that oxidized
phospholipids upregulated expression of ARE-containing
genes in murine bone marrow-derived macrophages [19].
TGF-b has been suggested to have antiinflammatory prop-
erties [23], and it thought to be produced by alternatively
Table 2: Molecular network analysis using IPA (Continued)
#3 ATF7IP, ATPase, BACE1, CAPN3, CASP2, CASP7, CASP10, Caspase, CTRL, ENTPD2, hydrolase,
ICAM1, IDE, ITM2C, KIAA1632, KYNU, LGMN, MAGED1, MEOX2, NAIP, NANP, NGFR, NUP160,
PAPPA, peptidase, PLEKHF2 (includes EG:79666), RECQL5, RTN3, SENP5 (includes EG:205564),
SPPL2B, SPTBN1, THTPA, UBAC2, UBR5, XAF1
32 31 Protein Degradation,
Protein Synthesis,
Post-Translational Modification
#4 API5, ARRDC3, ASPH, Calbindin, CKB, CNNM4, COX11, COX15, COX10 (includes EG:1352),
CPT1B, Creatine Kinase, Cytochrome c oxidase, ENO3, FICD, FOXP1, GPRASP2, HTR2B, HTT,
JAKMIP1, KLF16, NDUFS1, NEFH, PHB (includes EG:5245), PPP1R16B, RCOR2, REST, RGS14,
RNF34, SASH1, SCN4B, SNN, STRN, Thymidine Kinase, VAPA, WAC
32 31 Gene Expression,
Neurological Disease,
Cellular Compromise
#5 ALDH7A1, BPI, Cbp, Ciap, CLIP2, CST7, DBT, DUSP2, G0S2, GFPT2, KLF3, KRT19, lymphotoxin-
alpha1-beta2, MICA, NFkB (complex), NKIRAS1, PELI3, POU2F2, RBCK1, REL/RELA/RELB,
RNF216, S100P, S100Z, SH3RF1, SIAH2, SLC2A6, SNIP1, SUMO4, TNIP2, TRIM32, TRIM69,
TXNRD1, WTAP, ZMYND11, ZNF71
30 30 Carbohydrate Metabolism,
Lipid Metabolism,
Small Molecule Biochemistry
Molecular network analysis was performed using IPA software. The top 5 groups of molecules in the network are listed in order of network score, which IPA
calculates as shown below. We focused on the highest scoring network #1 in M1 macrophages, which had a score of 41 and included 35 molecules matched
with the Ingenuity Knowledge Base.
Network Score = -log10(P-value)
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Page 11 of 18Figure 4 Molecular network analysis of the highest scoring network in Table 2. The molecular network in network #1 of M1 macrophages
shown in Table 2 and corresponding data of M0 and M2 macrophages are shown. Nearly all the molecules in M1 were related to TGF-b1
directly or indirectly. Molecules are represented as nodes, and the biological relationships between pairs of nodes are represented as lines. The
intensity of the node color indicates the degree of upregulation (red) or downregulation (blue). The numbers below the nodes denote fold
changes (log2 ratio) of normalized intensities during oxLDL treatment. Nodes are displayed using various shapes representing the functional class
of the gene product. Lines are displayed with various labels describing the nature of the relationship between the nodes; i.e., A for Activation, E
for Expression, LO for Localization, PD for Protein - DNA binding, PP for Protein - Protein binding, RB for Regulation of Binding, and T for
Transcription.
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Page 12 of 18activated macrophages [24]. Activation of M1 macrophages
might be altered by M2-derived TGF-b.A sT G F - b downre-
gulates scavenger receptors, such as scavenger receptor type
A (SR-A) I/II and CD36 [25], and upregulates ATP-binding
cassette (ABC) transporters, ABCA1 and ABCG1 [26],
TGF-b is also thought to have protective effects against the
development of atherosclerosis. However, the contribution
of TGF-b to the development of atherosclerosis is more
complicated, taking account of clinical data. It is controver-
sial whether TGF-b levels in blood from patients are posi-
tively or negatively correlated with cardiovascular disease
[27]. In molecular network analysis, the molecules in the
highest scoring network of M1 macrophages, but not M0 or
M2, were related directly or indirectly to TGF-b1( F i g u r e4 ) .
However, no molecules in the known TGF-b signal trans-
duction pathway, including TGF-b receptors (TbRs) and
SMADs, were altered by oxLDL treatment in this study.
The results of cDNA microarray analysis (Figure 4) and
real-time RT-PCR analysis (data not shown) indicated that
oxLDL treatment slightly induced TGF-b1 gene expression
in M1 macrophages. TGF-b generally plays an important
role in maintaining normal vessel wall conditions, including
the expression of contractile proteins in vascular smooth
muscle cells (VSMCs) [28]. Under atherogenic conditions,
however, TGF-b reduces extracellular matrix production
from VSMCs and enhances leukocytes recruitment to ather-
osclerotic plaques, resulting in plaque rupture. Our results
suggest that TGF-b-related molecules were affected by
oxLDL stimulation, and that TGF-b promoted proinflam-
matory activities in M1 macrophages as in VSMCs. These
findings suggest that oxLDL regulates the functions of M1
macrophages through an as yet unknown TGF-b-mediated
cascade. It is therefore necessary to elucidate the detailed
TGF-b-related functions regulated by oxLDL stimulation in
various cells.
NF-B is present in an inactive form bound to an inhi-
bitor protein (I-B) in the cytoplasm. On stimulation,
NF-Bi sr e l e a s e df r o mI - B, is translocated to the
nucleus, and binds to the promoter DNA, followed by
production of many types of inflammatory cytokine
[29,30]. The NF-B signaling pathway is known to be
activated by oxLDL in a CD36-dependent manner [31].
Interestingly, cluster B included genes related to the NF-
B signaling pathway, such as NF-B and PI3K (Figure 5
Table 3). The results of molecular network analysis indi-
cated that oxLDL treatment induced upregulation of the
growth factor receptor-mediated NF-B signaling path-
w a yi nM 1b u tn o tM 0o rM 2m a c r o p h a g e s ,w h i l eI - B
was upregulated in M0 and M2 but not M1 (Additional
file 2). Thus, it seems that oxLDL stimulated the NF-B
signaling pathway specifically in M1.
There have been some reports partially conflicting
with this study [10,11], probably due to differences in
experimental conditions, such as oxLDL concentrations,
TBARS levels, or duration of treatment. Further studies
are required to determine whether M1 macrophages
contribute to foam cell formation. In this study, we pri-
marily measured mRNA levels, and all samples were
obtained from healthy volunteers. Measurements of pro-
tein levels and data derived from atherosclerotic subjects
should be included in the next study.
Conclusions
The present study demonstrated the effects of oxLDL on
transcriptional alterations in polarized macrophages.
The data suggested that oxLDL uptake may affect TGF-
b1- and NF-B-mediated functions of M1 macrophages,
but not M0 or M2 macrophages. It is likely that M1
macrophages characteristically respond to oxLDL.
Further studies are required to evaluate the roles of
TGF-b1- and NF-B-mediated macrophage functions in
the early stages of foam cell formation.
Figure 5 Heat map constructed by hierarchical cluster analysis.
Red and green in the heat maps indicate up- and downregulation
during oxLDL treatment, respectively. The left map includes 3196
genes expression levels of which were significantly altered by oxLDL
treatment in at least one subset of macrophages. Genes in three
clusters, denoted as A to C, were specifically upregulated only in
one subset. There were 17, 72, and 28 annotated genes in cluster A,
B, and C, respectively (right map).
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Page 13 of 18Table 3 Genes included in each cluster
Cluster A.
Gene
Symbol
Ref Seq ID M0 M1 M2 NCBI official full name
CHI3L2 NM_004000 1.170712 0.008113 -0.453072 chitinase 3-like 2
PARP8 NM_024615 1.018767 0.147437 -0.206628 poly (ADP-ribose) polymerase family, member 8
MAP4K4 NM_145686 1.115230 -0.302140 -0.763189 mitogen-activated protein kinase kinase kinase kinase 4
CD44 NM_001001391 1.312520 -0.201936 -0.048693 CD44 molecule
CYP27B1 NM_000785 1.111109 -0.055705 -0.015432 cytochrome P450, family 27, subfamily B, polypeptide 1
SLC1A2 NM_004171 1.466166 -0.088519 0.225126 solute carrier family 1 (glial high affinity glutamate transporter), member 2
CKMT1 NM_020990 1.436353 0.264923 0.338353 creatine kinase, mitochondrial 1B
MYOD1 NM_002478 1.665245 0.211625 0.330158 myogenic differentiation 1
CD40 NM_001250 1.319905 -0.606033 0.379319 CD40 molecule, TNF receptor superfamily member 5
PRKAR2B NM_002736 1.349370 -0.472458 0.347752 protein kinase, cAMP-dependent, regulatory, type II, beta
KIAA0913 NM_015037 1.244477 -0.318545 0.447287 KIAA0913
SNX10 NM_013322 1.138265 -0.351416 0.635676 sorting nexin 10
HHIP NM_022475 1.177555 -0.537186 0.506197 hedgehog interacting protein
BIRC3 NM_001165 1.499122 -0.583781 -0.065715 baculoviral IAP repeat-containing 3
ZBTB7C NM_001039360 1.293925 -1.001009 0.404020 zinc finger and BTB domain containing 7C
PACRGL NM_145048 2.026548 -0.460488 0.187722 PARK2 co-regulated-like
CCL23 NM_005064 2.471357 -0.192407 -0.036793 chemokine (C-C motif) ligand 23
Cluster B.
Gene
Symbol
Ref Seq ID M0 M1 M2 NCBI official full name
NDN NM_002487 -0.169667 1.457695 -0.617320 necdin homolog (mouse)
FAM129C NM_173544 -0.110208 1.321559 -0.841954 family with sequence similarity 129, member C
NME6 NM_005793 -0.315804 1.345342 -0.759802 non-metastatic cells 6, protein expressed in (nucleoside-diphosphate kinase)
TMEM99 NM_145274 -0.390527 1.497197 -0.676125 transmembrane protein 99
ATP2B1 NM_001682 -0.371182 1.535878 -0.824423 ATPase, Ca++ transporting, plasma membrane 1
KIF1A NM_004321 -0.362399 1.333531 -0.928733 kinesin family member 1A
TMEM188 NM_153261 -0.375073 1.157188 -0.955238 transmembrane protein 188
PLEKHG4 NM_015432 -0.414580 1.052587 -0.706013 pleckstrin homology domain containing, family G (with RhoGef domain) member
4
NOXA1 NM_006647 -0.322207 1.015456 -0.592170 NADPH oxidase activator 1
CUX1 NM_001913 -0.236206 1.147118 -0.551592 cut-like homeobox 1
SBNO2 NM_014963 -0.294540 1.271977 -0.630553 strawberry notch homolog 2 (Drosophila)
TIGD5 NM_032862 -0.376362 1.224225 -0.526717 tigger transposable element derived 5
CTSL2 NM_001333 -0.428772 1.153800 -0.359408 cathepsin L2
ZNF24 NM_006965 -0.385988 1.069071 -0.360632 zinc finger protein 24
STK32C NM_173575 -0.634840 1.124350 -0.544619 serine/threonine kinase 32C
NUDT17 NM_001012758 -0.524910 1.111636 -0.519731 nudix (nucleoside diphosphate linked moiety X)-type motif 17
CALML4 NM_033429 -0.433422 1.089113 -0.492229 calmodulin-like 4
C7orf33 NM_145304 -0.435642 1.106760 -0.512504 chromosome 7 open reading frame 33
FBXO22 NM_012170 -0.203452 1.309369 -0.481216 F-box protein 22
LINGO1 NM_032808 -0.174931 1.312372 -0.445152 leucine rich repeat and Ig domain containing 1
ZMYND19 NM_138462 -0.243665 1.351306 -0.517691 zinc finger, MYND-type containing 19
CCR1 NM_001295 -0.165232 1.419892 -0.480175 chemokine (C-C motif) receptor 1
ATRX NM_000489 -0.498685 1.285463 -0.371568 alpha thalassemia/mental retardation syndrome X-linked
FRMD4B NM_015123 -0.477381 1.252296 -0.287931 FERM domain containing 4B
CEP164 NM_014956 -0.419638 1.269277 -0.283263 centrosomal protein 164kDa
LANCL2 NM_018697 -0.393507 1.324253 -0.242555 LanC lantibiotic synthetase component C-like 2 (bacterial)
UBA5 NM_024818 -0.478021 1.390785 -0.479541 ubiquitin-like modifier activating enzyme 5
GGCX NM_000821 -0.380201 1.330677 -0.476370 gamma-glutamyl carboxylase
FOXN3 NM_005197 -0.772837 1.196028 -0.268613 forkhead box N3
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Page 14 of 18Table 3: Genes included in each cluster (Continued)
TP53BP1 NM_005657 -0.797822 1.249895 -0.460222 tumor protein p53 binding protein 1
ORC6 NM_014321 -0.633454 1.305326 -0.322922 origin recognition complex, subunit 6
ST7 NM_018412 -0.678132 1.309238 -0.290689 suppression of tumorigenicity 7
OGFOD1 NM_018233 0.061541 1.413933 -0.438702 2-oxoglutarate and iron-dependent oxygenase domain containing 1
UBE2B NM_003337 0.146284 1.431435 -0.295974 ubiquitin-conjugating enzyme E2B (RAD6 homolog)
GALNTL4 NM_198516 0.178950 1.470650 -0.270045 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 4
HSPA14 NM_016299 0.185892 1.419392 -0.264205 heat shock 70kDa protein 14
PEX13 NM_002618 0.137507 1.527385 -0.274508 peroxisomal biogenesis factor 13
ATP2B2 NM_001001331 0.084953 1.689567 -0.394052 ATPase, Ca++ transporting, plasma membrane 2
TAAR2 NM_014626 0.168770 1.695874 -0.439255 trace amine associated receptor 2
HUS1 NM_004507 0.098273 1.666199 -0.226370 HUS1 checkpoint homolog (S. pombe)
RIC8B NM_018157 0.214093 1.650594 -0.307883 resistance to inhibitors of cholinesterase 8 homolog B (C. elegans)
DNAJC17 NM_018163 0.172153 1.482705 -0.492935 DnaJ (Hsp40) homolog, subfamily C, member 17
TMEM130 NM_152913 0.206368 1.399311 -0.480833 transmembrane protein 130
AP2A2 NM_012305 0.285524 1.391232 -0.458091 adaptor-related protein complex 2, alpha 2 subunit
TTTY13 NR_001537 0.381981 1.560081 -0.451429 testis-specific transcript, Y-linked 13 (non-protein coding)
AKT1S1 NM_032375 0.385837 1.517956 -0.371995 AKT1 substrate 1 (proline-rich)
WNT3 NM_030753 0.009319 1.560600 -0.801987 wingless-type MMTV integration site family, member 3
ZNF443 NM_005815 0.154517 1.457293 -0.742146 zinc finger protein 443
TFCP2L1 NM_014553 0.207710 1.525949 -0.955561 transcription factor CP2-like 1
KIAA0355 NM_014686 0.278629 1.724807 -0.576470 KIAA0355
ASAP2 NM_003887 0.524513 1.733462 -0.459752 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2
C14orf49 NM_152592 0.578042 1.624871 -0.365254 chromosome 14 open reading frame 49
NFKB2 NM_002502 0.652839 1.882528 -0.343188 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
ZNF586 NM_017652 0.328381 1.848104 -0.284595 zinc finger protein 586
RNMTL1 NM_018146 0.277170 1.645924 -0.133286 RNA methyltransferase like 1
FOSL2 NM_005253 0.386974 1.569486 -0.229451 FOS-like antigen 2
SATB1 NM_002971 0.542138 1.252296 -0.749110 SATB homeobox 1
ASB6 NM_177999 0.666548 1.536652 -0.584820 ankyrin repeat and SOCS box-containing 6
SLC5A3 NM_006933 0.682674 1.388148 -0.424733 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3
C8orf84 NM_153225 0.637255 1.709652 -0.981619 chromosome 8 open reading frame 84
MON1B NM_014940 0.234404 2.712191 -0.753618 MON1 homolog B (yeast)
PIGO NM_152850 0.134053 2.574539 -0.004491 phosphatidylinositol glycan anchor biosynthesis, class O
STAM NM_003473 -0.221822 2.697280 -0.150394 signal transducing adaptor molecule (SH3 domain and ITAM motif) 1
CCDC45 NM_138363 -0.046055 2.118025 -0.312274 coiled-coil domain containing 45
GYS1 NM_002103 -0.699205 1.685994 -0.629003 glycogen synthase 1 (muscle)
RENBP NM_002910 -0.403657 1.957579 -0.580833 renin binding protein
BTD NM_000060 -0.348646 1.647239 -0.685758 biotinidase
FAM172A NM_032042 -0.409833 1.717425 -0.665763 family with sequence similarity 172, member A
PIK3R4 NM_014602 -0.188899 2.325311 -0.729078 phosphoinositide-3-kinase, regulatory subunit 4
RSAD1 NM_018346 -0.251002 2.260460 -0.748812 radical S-adenosyl methionine domain containing 1
ZNF626 NM_145297 -0.252970 1.842391 -0.910235 zinc finger protein 626
CTH NM_001902 -1.060839 2.365953 -1.038817 cystathionase (cystathionine gamma-lyase)
Cluster C.
Gene
Symbol
Ref Seq ID M0 M1 M2 NCBI official full name
MXD3 NM_031300 -0.800223 0.116059 1.984245 MAX dimerization protein 3
CD14 NM_000591 -1.193454 -0.266058 2.053786 CD14 molecule
BARX1 NM_021570 -1.650218 0.236670 1.728783 BARX homeobox 1
ZNF331 NM_018555 -1.729498 -0.028187 1.786943 zinc finger protein 331
GPR54 NM_032551 -0.085064 -0.929503 1.669680 KISS1 receptor
Hirose et al. Lipids in Health and Disease 2011, 10:1
http://www.lipidworld.com/content/10/1/1
Page 15 of 18Table 3: Genes included in each cluster (Continued)
ANP32A NM_006305 -0.155917 -0.929503 1.827632 acidic (leucine-rich) nuclear phosphoprotein 32 family, member A
C19orf54 NM_198476 -0.205921 -0.803972 1.634746 chromosome 19 open reading frame 54
G0S2 NM_015714 -0.367904 -0.858834 2.131860 G0/G1switch 2
SPATA3 NM_139073 -0.301818 -0.432004 1.766064 spermatogenesis associated 3
FOXA2 NM_153675 -0.306075 -0.533883 1.983144 forkhead box A2
PSORS1C2 NM_014069 -0.423428 -0.713119 1.449567 psoriasis susceptibility 1 candidate 2
SNN NM_003498 -0.492216 -1.239138 1.185086 stannin
CDKN2B NM_078487 -0.404103 -0.847300 1.024029 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
ZNF257 NM_033468 -0.916132 -1.388935 1.189490 zinc finger protein 257
ZBTB4 NM_020899 -0.296438 -1.533325 0.937391 zinc finger and BTB domain containing 4
CASP2 NM_032983 -1.527530 -0.751505 1.026536 caspase 2, apoptosis-related cysteine peptidase
TCTEX1D1 NM_152665 -1.661006 -0.348442 1.280638 Tctex1 domain containing 1
FILIP1L NM_014890 -0.967885 -0.212315 1.018932 filamin A interacting protein 1-like
USP52 NM_014871 -0.885665 -0.310932 1.097774 PAN2 poly(A) specific ribonuclease subunit homolog (S. cerevisiae)
SETD8 NM_020382 -1.020324 -0.599401 0.697655 SET domain containing (lysine methyltransferase) 8
C13orf31 NM_153218 -1.442594 -0.330041 0.688789 chromosome 13 open reading frame 31
POLD1 NM_002691 -1.311086 -0.314006 0.812769 polymerase (DNA directed), delta 1, catalytic subunit 125kDa
DNMT3A NM_022552 -1.207327 -0.289399 0.489584 DNA (cytosine-5-)-methyltransferase 3 alpha
TGFBI NM_000358 -1.324217 -0.324120 0.308245 transforming growth factor, beta-induced, 68kDa
ANP32C NM_012403 -1.493138 -0.380761 0.494101 acidic (leucine-rich) nuclear phosphoprotein 32 family, member C
ITGA2B NM_000419 -1.109218 0.018385 1.026536 integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)
RGS3 NM_130795 -1.022299 -0.038087 0.656812 regulator of G-protein signaling 3provided
MARCH1 NM_017923 -1.374411 0.233896 0.729622 membrane-associated ring finger (C3HC4) 1provided
The top functional ontology
categories
Cluster A. P-value
Cell-mediated Immune Response 9.46E-06-2.65E-02
Cellular Movement 9.46E-06-3.76E-02
Hematological System Development
and Function
9.46E-06-3.57E-02
Immune Cell Trafficking 9.46E-06-2.49E-02
Cardiovascular Disease 2.64E-05-3.76E-02
Cluster B. P-value
Cell Cycle 1.31E-04-3.28E-02
Cell Cycle 1.31E-04-3.28E-02
DNA Replication, Recombination,
and Repair
1.31E-04-4.51E-02
Gene Expression 2.16E-03-3.35E-02
Cellular Development 3.51E-03-3.64E-02
Nervous System Development and
Function
3.51E-03-4.7E-02
Cluster C. P-value
Carbohydrate Metabolism 1.12E-04-4.09E-02
Lipid Metabolism 1.12E-04-4.09E-02
Small Molecule Biochemistry 1.12E-04-4.09E-02
Cell Death 3.76E-04-4.81E-02
Nervous System Development and
Function
7.79E-04-3.33E-02
Three clusters were extracted from the heat map shown in Figure 5. There were 17, 72, and 28 annotated genes in clusters A, B, and C, respectively. The top
functional ontology categories and the corresponding P-values in each subset are shown. NFKB2 and PIK3R4 were found in cluster B. The values denote fold
changes (log2 ratio) of normalized intensities during oxLDL treatment.
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Additional file 1: All transcriptional profile. After eliminated controls
and backgrounds from all the probe sets on “3D-Gene” human oligo
chip 25 k, the remained 24267 probe sets are listed. The values denote
fold changes (log2 ratio) of normalized intensities during oxLDL
treatment. Pink and blue cells indicate the genes showing a change in
expression of >2-fold during oxLDL treatment as significantly up- or
downregulated (log2 ratios were greater than +1 or less than -1). Genes
intensities of which were less than 2
-4 are shown as blank cells.
Additional file 2: Molecular network focusing on the NF-B
signaling pathway. This network consisted of the known NF-B
signaling pathway. The intensity of the node color indicates the degree
of upregulation (red) or downregulation (blue). Nodes are displayed
using various shapes represent the functional class of the gene product.
Lines are displayed with various labels that describe the nature of the
relationship between the nodes: A for Activation, M for Biochemical
Modification, P for Phosphorylation/Dephosphorylation, PP for Protein -
Protein binding, PR for Protein - RNA binding, RB for Regulation of
Binding, T for Transcription, and TR for Translocation. The growth factor
receptor-mediated NF-B signaling pathway was upregulated in M1, but
not in M0 or M2 macrophages.
Acknowledgements and Funding
This study was supported in part by the “High-Tech Research Center” Project
for Private Universities: matching fund subsidy, by a Grant-in-Aide (S0991013)
for the Foundation of Strategic Research Projects in Private Universities from
Ministry of Education, Culture, Sport, Science, and Technology, Japan, and by
the Mizutani Foundation for Glycoscience (to K. I.).
Author details
1Department of Cardiovascular Medicine, Juntendo University School of
Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
2Institute for
Environmental and Gender Specific Medicine, Juntendo University Graduate
School of Medicine, 2-1-1, Tomioka, Urayasu City, Chiba 278-0021, Japan.
Authors’ contributions
KI, KS, and HD designed the study. KH participated at all stages and drafted
the manuscript. CI conducted cDNA microarray analysis, HN performed flow
cytometry analysis, and TK provided valuable help with cell cultures. KH, CI
and HN analyzed the data together with KI, KS, and HD. KH, KI, and KS co-
wrote the paper. All authors read and approved the final draft of the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 November 2010 Accepted: 4 January 2011
Published: 4 January 2011
References
1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM,
Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J,
Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, Thom T,
Wilson M, Hong Y: Heart disease and stroke statistics–2008 update: a
report from the American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Circulation 2008, 117:e25-146.
2. Rocha VZ, Libby P: Obesity, inflammation, and atherosclerosis. Nat Rev
Cardiol 2009, 6:399-409.
3. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature 1993, 362:801-809.
4. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T,
Leonard EJ, Witztum JL, Steinberg D: Expression of monocyte
chemoattractant protein 1 in macrophage-rich areas of human and
rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991, 88:5252-5256.
5. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A: Interleukin 8 is
induced by cholesterol loading of macrophages and expressed by
macrophage foam cells in human atheroma. J Biol Chem 1996,
271:8837-8842.
6. Ardans JA, Economou AP, Martinson JM, Zhou M, Wahl LM: Oxidized low-
density and high-density lipoproteins regulate the production of matrix
metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol 2002,
71:1012-1018.
7. Stein M, Keshav S, Harris N, Gordon S: Interleukin 4 potently enhances
murine macrophage mannose receptor activity: a marker of alternative
immunologic macrophage activation. J Exp Med 1992, 176:287-292.
8. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003,
3:23-35.
Figure 6 Quantitative real-time RT-PCR.A .IL8 mRNA expression
levels. The expression level of IL8 was significantly upregulated by
oxLDL treatment in M1 macrophages (P < 0.05). IL8 expression level
after oxLDL treatment in M2 was markedly lower than those in M0
and M1 macrophages (P < 0.05). B. HMOX1 mRNA expression levels.
OxLDL treatment significantly enhanced HMOX1 gene expression by
7.6-fold (**P < 0.0005), 5.8-fold (*P < 0.05), and 5.9-fold (*P < 0.05) in
M0, M1, and M2 macrophages, respectively. HMOX1 gene expression
levels were almost the same in all 3 subsets of macrophages even
after oxLDL treatment. Each bar shows the mean ± SD of 3
experiments.
Hirose et al. Lipids in Health and Disease 2011, 10:1
http://www.lipidworld.com/content/10/1/1
Page 17 of 189. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S,
Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G:
PPARgamma activation primes human monocytes into alternative M2
macrophages with anti-inflammatory properties. Cell Me tab 2007,
6:137-143.
10. Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of
the human monocyte-to-macrophage differentiation and polarization:
new molecules and patterns of gene expression. J Immunol 2006,
177:7303-7311.
11. Cho HJ, Shashkin P, Gleissner CA, Dunson D, Jain N, Lee JK, Miller Y, Ley K:
Induction of dendritic cell-like phenotype in macrophages during foam
cell formation. Physiol Genomics 2007, 29:149-160.
12. Iwabuchi K, Nagaoka I: Lactosylceramide-enriched glycosphingolipid
signaling domain mediates superoxide generation from human
neutrophils. Blood 2002, 100:1454-1464.
13. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK: Oxidized
LDL induces monocytic cell expression of interleukin-8, a chemokine
with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994,
14:47-53.
14. Kiyanagi T, Iwabuchi K, Shimada K, Hirose K, Miyazaki T, Sumiyoshi K,
Iwahara C, Nakayama H, Masuda H, Mokuno H, Sato S, Daida H:
Involvement of Cholesterol-enriched Microdomains in Class A Scavenger
Receptor-mediated Responses in Human Macrophages. Atherosclerosis .
15. Standiford TJ, Strieter RM, Chensue SW, Westwick J, Kasahara K, Kunkel SL:
IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J
Immunol 1990, 145:1435-1439.
16. Martin-Fuentes P, Civeira F, Recalde D, Garcia-Otin AL, Jarauta E, Marzo I,
Cenarro A: Individual variation of scavenger receptor expression in
human macrophages with oxidized low-density lipoprotein is associated
with a differential inflammatory response. J Immunol 2007,
179:3242-3248.
17. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ,
Flavell RA, Choi AM: Carbon monoxide has anti-inflammatory effects
involving the mitogen-activated protein kinase pathway. Nat Med 2000,
6:422-428.
18. Morita T: Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc
Biol 2005, 25:1786-1795.
19. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR,
Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE,
Wamhoff BR, Leitinger N: Identification of a novel macrophage
phenotype that develops in response to atherogenic phospholipids via
Nrf2. Circ Res 2010, 107:737-746.
20. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N,
Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf
heterodimer mediates the induction of phase II detoxifying enzyme
genes through antioxidant response elements. Biochem Biophys Res
Commun 1997, 236:313-322.
21. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL: Nrf2, a
Cap’n’Collar transcription factor, regulates induction of the heme
oxygenase-1 gene. J Biol Chem 1999, 274:26071-26078.
22. Kobayashi A, Ohta T, Yamamoto M: Unique function of the Nrf2-Keap1
pathway in the inducible expression of antioxidant and detoxifying
enzymes. Methods Enzymol 2004, 378:273-286.
23. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R,
Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted
disruption of the mouse transforming growth factor-beta 1 gene results
in multifocal inflammatory disease. Nature 1992, 359:693-699.
24. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM,
Gotwals P, Noble P, Chen Q, Senior RM, Elias JA: Interleukin-13 induces
tissue fibrosis by selectively stimulating and activating transforming
growth factor beta(1). J Exp Med 2001, 194:809-821.
25. Draude G, Lorenz RL: TGF-beta1 downregulates CD36 and scavenger
receptor A but upregulates LOX-1 in human macrophages. Am J Physiol
Heart Circ Physiol 2000, 278:H1042-1048.
26. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA,
Wolfe BM, Huff MW: Transforming growth factor-beta1 inhibits
macrophage cholesteryl ester accumulation induced by native and
oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001, 21:2011-2018.
27. Grainger DJ: TGF-beta and atherosclerosis in man. Cardiovasc Res 2007,
74:213-222.
28. Grainger DJ: Transforming growth factor beta and atherosclerosis: so far,
so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc
Biol 2004, 24:399-404.
29. Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the
immune system. Annu Rev Immunol 1994, 12:141-179.
30. Lenardo MJ, Baltimore D: NF-kappa B: a pleiotropic mediator of inducible
and tissue-specific gene control. Cell 1989, 58:227-229.
31. Janabi M, Yamashita S, Hirano K, Sakai N, Hiraoka H, Matsumoto K, Zhang Z,
Nozaki S, Matsuzawa Y: Oxidized LDL-induced NF-kappa B activation and
subsequent expression of proinflammatory genes are defective in
monocyte-derived macrophages from CD36-deficient patients. Arterioscler
Thromb Vasc Biol 2000, 20:1953-1960.
doi:10.1186/1476-511X-10-1
Cite this article as: Hirose et al.: Different responses to oxidized low-
density lipoproteins in human polarized macrophages. Lipids in Health
and Disease 2011 10:1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hirose et al. Lipids in Health and Disease 2011, 10:1
http://www.lipidworld.com/content/10/1/1
Page 18 of 18